Vect-Horus

Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals

Emmanuelle BETTENDORF — 2026-02-03T14:28:27Z

We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.

“We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus' leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with Pharma and Biotech companies like OliX,” said Alexandre Tokay, CEO of Vect-Horus.

“This partnership has the potential to accelerate the development of innovative treatments and bring renewed hope to patients worldwide, and we are looking forward to a strong collaboration with OliX.”

https://www.globenewswire.com/news-release/2026/02/03/3230746/0/en/Vect-Horus-Enters-a-CNS-Focused-Research-Collaboration-with-OliX-Pharmaceuticals.html

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC

Emmanuelle BETTENDORF — 2025-09-19T13:36:02Z

Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).

“The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.

“We are looking forward to generating clinical data together with RadioMedix with the aim of expanding the therapeutic treatment options available to patients with GBM and PDAC.”

👉 https://www.globenewswire.com/news-...

Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders

Emmanuelle BETTENDORF — 2025-07-11T09:08:57Z

We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!

The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna's proprietary OligoCreator® oligonucleotide discovery platform.

The combination of these two technologies will expand Secarna's targeted delivery portfolio, offering a novel approach that could potentially transform the treatment of neurodegenerative diseases.

“This research collaboration represents a unique opportunity to overcome the long-standing delivery challenges through the blood-brain barrier and bring forward innovative treatment options for patients who today have limited and ineffective treatment option,” says Alexandre Tokay, co-founder and CEO of Vect-Horus.

Click here for the full press release : https://www.globenewswire.com/fr/news-release/2025/07/10/3113000/0/fr/Secarna-Pharmaceuticals-et-Vect-Horus-annoncent-un-programme-de-recherche-pour-le-transport-cibl%C3%A9-des-th%C3%A9rapies-visant-l-ARN-pour-traiter-les-maladies-du-syst%C3%A8me-nerveux-central.html

Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors

Emmanuelle BETTENDORF — 2025-02-03T12:57:00Z

We are excited that Jerome Berger is joining our Board of Directors!

Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.

“Jerome's unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we aim to revolutionize targeted drug delivery,” says Alexandre Tokay, co-founder and CEO of Vect-Horus.

Press Release available here

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Emmanuelle BETTENDORF — 2024-01-30T13:24:06Z

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus' platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system. Ionis has an option to add additional targets to the license. Vect-Horus retains the rights to use its technology, for these specific targets, for all non-RNA-Targeted Medicines.

Under the terms of the agreement, Vect-Horus will receive a double-digit million-dollar upfront payment. Vect-Horus will be eligible to receive development, regulatory and commercial milestone payments and tiered single digit royalties on annual product sales.

“We are extremely pleased to partner with Ionis, a pioneer in RNA-targeted medicines, to tackle one of the toughest problems in RNA therapeutics, systemic delivery of therapeutics across the blood-brain barrier,” said Alexandre Tokay co-founder and CEO of Vect-Horus. “This license is aligned with our strategy of using our technology to deliver drug payloads, such as RNA-targeted therapeutics, to the brain and other tissues. We hope that combining our technology with Ionis' industry-leading RNA-targeted drug platform will enable the creation of innovative medicines for a variety of neurological diseases.”

"With a proven track record of delivering first-in-class disease modifying medicines for serious neurological diseases, we believe we are well positioned to tackle the next frontier of delivery of neurology medicines across the blood-brain barrier," said Eric E. Swayze, Ph.D., Ionis' executive vice president of research. "Vect-Horus' promising technology represents a strategic addition to our industry-leading RNA technologies, providing us with the potential to bring systemically-delivered medicines to patients in need of treatment options across both rare and common neurological diseases.”

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Emmanuelle BETTENDORF — 2023-11-01T05:35:57Z

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the license.
Under the terms of the agreement, Vect-Horus will receive an upfront payment and up to $327 million in additional potential development, regulatory and commercial milestones across 3 programs. In addition, Vect-Horus is eligible to receive tiered royalties on product sales.
“We are extremely pleased to partner with Novo Nordisk, a leading global healthcare company. This is an important collaboration for Vect-Horus that underscores the potential of our approach to facilitate the targeting of molecules to different organs”, said Alexandre Tokay, co-founder and CEO of Vect-Horus. “This agreement is another important step in our strategy to establish commercial partnerships and to secure significant short-term cash to implement our technology and development programs. We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments”.
"Ability to accurately target delivery of therapeutics is critical to our ambition to address unmet needs within serious chronic diseases," said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk. "We are thrilled to work with Vect-Horus by leveraging their platform to discover optimal delivery for specified targets. It is an exemplary opportunity for us to utilize external collaboration to further fuel our own innovation processes, with a common goal of improving health outcomes."

Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents

Elodie DORMES — 2020-11-17T16:00:32Z

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS' theragnostic agents.

CERIMED, also based in the Timone Aix-Marseille University Campus, has expertise in medical imaging techniques (PET, SPECT, etc.) and provides a complete platform of in vivo preclinical and clinical imaging entirely dedicated to R&D of innovative clinical imaging tools.

VECT-HORUS is co-developing with RADIOMEDIX (Tx, USA) one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma. VECT-HORUS also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

“CERIMED offers a wide range of services in medical imaging, and we are tremendously pleased to work with them. This partnership is fully aligned with our strategy to collaborate with Regional Centers and to expand the use of our VECTrans® technology in the theragnostic field,” said Jamal Temsamani, Ph.D., Director of Drug Development of VECT-HORUS.

“CERIMED is very proud to announce the initiation of this collaboration with VECT-HORUS. The respective expertise of VECT-HORUS and CERIMED makes this consortium a major asset in the development of new theragnostic approaches to oncological pathology” said Pr Benjamin Guillet, director of CERIMED, head of radiopharmaceutical department of Marseille University Hospital and of Drug Department of Pharmacy faculty of Aix-Marseille University.

Full article available at
https://www.businesswire.com/news/home/20201117005010/en/VECT-HORUS-and-CERIMED-Announce-Collaboration-to-Support-the-Development-of-VECT-HORUS%E2%80%99-Theragnostic-Agents

Relocation of the company to support its development

Elodie DORMES — 2019-10-01T17:48:58Z

Vect-Horus develops inventions and technologies derived from the BBB and Neuroinflammation Team in the Institute of NeuroPhysiopathology (INP-UMR7051) directed by Dr. Michel Khrestchatisky, also cofounder of the company. Vect-Horus has established a long-term highly efficient collaboration with the BBB and Neuroinflammation Team and is now member of the INP in the context of a “Laboratoire Commun de Recherche (LCR)” as the basis for a solid academic-industry partnership.

The company has also interactions with other academic laboratories in Marseille (INT, CERIMED, CRCM, ICR etc.), and Paris region (CEA Saclay, Inserm Paris etc.).

Moreover, the company has established a number of research partnerships with biotechnology and pharma companies and is continuing its intensive international development. This relocation in larger space supports its development.

With 32 employees, 30 of whom are scientists, Vect-Horus develops its expertise around research platforms including the discovery and chemical optimization of vectors, the development and production of conjugates via chemistry or genetic engineering approaches, in vitro BBB models based on endothelial cells from rodents or human, derived from iPSc, Oncology and Pharmacology.

Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma

Jonathan NOWAK — 2019-06-04T18:20:51Z

Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas' antibody to the brain for the treatment of CNS diseases.


Press release

Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.

Jonathan NOWAK — 2019-03-26T11:00:00Z

Vect-Horus S.A.S. (Marseille, France) announced today that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development of novel molecules targeting neurodegenerative diseases.

Under the agreement, Vect-Horus will receive research fees, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Vect-Horus will apply its proprietary VECTrans® technology, which facilitates the transport of drugs into the brain, to ONO's therapeutic molecules. Vect-Horus will utilize its expertise to conjugate these therapeutic molecules with its peptide vectors and demonstrate improved brain uptake and efficacy in animals. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

“We are delighted to partner with Ono, one of the oldest pharmaceutical companies in the world and an important developer of innovative drugs,” commented Alexandre Tokay, Chief Executive Officer and cofounder of Vect-Horus. “Our agreement with Ono strengthens our long-standing commitment to improve, using our technology, the brain delivery of therapeutic molecules and bring forward novel therapies that address critical unmet needs.”

About Vect-Horus
Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules.
Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit www.vect-horus.com. For more information about this press release, please contact Elodie Dormes, Business Development Manager of Vect-Horus: contact@vect-horus.com.